Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
| ▸ | EPOR | P19235 | 6/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | SCNN1A | P37088 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1134542 | 0.99 | KCNH2 (0.60) | KCNH2EPORLTA4HEPHX2SCNN1A | |
| SCHEMBL1134581 | 0.92 | KCNH2 (0.72) | KCNH2EPORSCNN1AKDM4E | |
| SCHEMBL11980209 | 0.91 | KCNH2 (0.62) | KCNH2EPORLTA4HEPHX2SCNN1A | |
| SCHEMBL11959314 | 0.89 | KCNH2 (0.64) | KCNH2EPORLTA4HEPHX2SCNN1A | |
| Iodide SCHEMBL1428394 | 0.89 | KCNH2 (0.63) | KCNH2EPORLTA4HEPHX2SCNN1A | |
| Trifluoroacetic Acid SCHEMBL1134632 | 0.88 | KCNH2 (0.67) | KCNH2EPORSCNN1A | |
| SCHEMBL1428391 | 0.85 | KCNH2 (0.56) | KCNH2EPORLTA4HEPHX2SCNN1A | |
| SCHEMBL16541811 | 0.83 | KCNH2 (0.65) | KCNH2LTA4HEPHX2SCNN1AKDM4E | |
| SCHEMBL11959364 | 0.83 | KCNH2 (0.87) | KCNH2LTA4HEPHX2SCNN1AKDM4E | |
| SCHEMBL13573266 | 0.83 | KCNH2 (0.85) | KCNH2LTA4HEPHX2SCNN1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059989-A1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF AIRWAY DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | US | claimed |
| US-8664228-B2 | 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of airway diseases | NOVARTIS AG (CH) | 2014-03-04 | — | — | US | disclosed |
| US-8664228-B2 | 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of airway diseases | NOVARTIS AG (CH) | 2014-03-04 | — | — | US | disclosed |
| US-20110059989-A1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF AIRWAY DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | US | disclosed |
| US-20110059989-A1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF AIRWAY DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | US | disclosed |
| US-20110059989-A1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF AIRWAY DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059989-A1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF AIRWAY DISEASES | CFTR, SCN5A, SCNN1B | KCNH2 18/4885EPOR 943/4885LTA4H 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.